ArticleJournal of pain research2019

ATHENA: A Phase 3, Open-Label Study Of The Safety And Effectiveness Of Oliceridine (TRV130), A G-Protein Selective Agonist At The µ-Opioid Receptor, In Patients With Moderate To Severe Acute Pain Requiring Parenteral Opioid Therapy.

Sergio D Bergese et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.